Cargando…

Chemoradiation for cervical cancer treatment portends high risk of pelvic floor dysfunction

GOAL: To assess the impact of chemoradiation on pelvic floor (PF) muscle function after the treatment of cervical cancer (CC). METHODS: We performed a prospective cohort study of women between the ages of 20 and 70 years old who had a diagnosis of CC. Patients were treated with chemoradiation at the...

Descripción completa

Detalles Bibliográficos
Autores principales: Miguel, Taís Pereira, Laurienzo, Carla Elaine, Faria, Eliney Ferreira, Sarri, Almir José, Castro, Isabela Queiroz, Júnior, Renato José Affonso, da Cunha Andrade, Carlos Eduardo Mattos, Vieira, Marcelo de Andrade, dos Reis, Ricardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292417/
https://www.ncbi.nlm.nih.gov/pubmed/32530941
http://dx.doi.org/10.1371/journal.pone.0234389
_version_ 1783546110067867648
author Miguel, Taís Pereira
Laurienzo, Carla Elaine
Faria, Eliney Ferreira
Sarri, Almir José
Castro, Isabela Queiroz
Júnior, Renato José Affonso
da Cunha Andrade, Carlos Eduardo Mattos
Vieira, Marcelo de Andrade
dos Reis, Ricardo
author_facet Miguel, Taís Pereira
Laurienzo, Carla Elaine
Faria, Eliney Ferreira
Sarri, Almir José
Castro, Isabela Queiroz
Júnior, Renato José Affonso
da Cunha Andrade, Carlos Eduardo Mattos
Vieira, Marcelo de Andrade
dos Reis, Ricardo
author_sort Miguel, Taís Pereira
collection PubMed
description GOAL: To assess the impact of chemoradiation on pelvic floor (PF) muscle function after the treatment of cervical cancer (CC). METHODS: We performed a prospective cohort study of women between the ages of 20 and 70 years old who had a diagnosis of CC. Patients were treated with chemoradiation at the Barretos Cancer Hospital (BCH), between August 2016 and July 2017. We performed three evaluations at different time points after chemoradiation treatment to compare changes in muscle function. Pelvic floor muscle function was assessed through perineometry (PNM) and surface electromyography (EMG) at the following time points: Pretreatment Moment 1 (M1): evaluated before chemoradiation; Moment 2 (M2): at the first follow-up medical visit (usually 3 to 4 months after treatment); and Moment 3 (M3): at the second follow-up medical visit (usually after 6 to 9 months after treatment). Mean vaginal squeeze pressure levels were determined by PNM and muscle electromyographic activity by EMG and the results were evaluated by Generalized Linear Model comparisons. RESULTS: Forty-nine patients were evaluated at M1; 35 at M2; and 32 at M3, so that 32 patients had all three muscle evaluations performed. There was a statistically significant increase in the frequency of women with urgency urinary incontinence at the M2 evaluation time (41.9%), compared to pretreatment M1 (18.6%), p<0.001. The means of the vaginal squeeze pressures reduced through M1 to M3 in the phasic (M1: 17.7 mmHg; M3: 11.27mmHg) and tonic contractions (M1: 10.56 mmHg; M3: 7.52mmHg), p = 0.01 and p = 0.03 respectively. There was no difference in pelvic floor function in the three evaluations M1-M3, measured by EMG. The pelvic floor strength assessed by PMN and their interactions with anthropometric, parity and hormonal status variables, showed that a high body mass index (BMI) significantly influenced decreases in pelvic floor muscle function before and after treatment. CONCLUSION: These results show that chemoradiation causes reduction of muscle function of the pelvic floor, especially in the late phase after the end of treatment. Both the high BMI and urgent urinary incontinence symptoms were related to decreased muscle strength.
format Online
Article
Text
id pubmed-7292417
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-72924172020-06-18 Chemoradiation for cervical cancer treatment portends high risk of pelvic floor dysfunction Miguel, Taís Pereira Laurienzo, Carla Elaine Faria, Eliney Ferreira Sarri, Almir José Castro, Isabela Queiroz Júnior, Renato José Affonso da Cunha Andrade, Carlos Eduardo Mattos Vieira, Marcelo de Andrade dos Reis, Ricardo PLoS One Research Article GOAL: To assess the impact of chemoradiation on pelvic floor (PF) muscle function after the treatment of cervical cancer (CC). METHODS: We performed a prospective cohort study of women between the ages of 20 and 70 years old who had a diagnosis of CC. Patients were treated with chemoradiation at the Barretos Cancer Hospital (BCH), between August 2016 and July 2017. We performed three evaluations at different time points after chemoradiation treatment to compare changes in muscle function. Pelvic floor muscle function was assessed through perineometry (PNM) and surface electromyography (EMG) at the following time points: Pretreatment Moment 1 (M1): evaluated before chemoradiation; Moment 2 (M2): at the first follow-up medical visit (usually 3 to 4 months after treatment); and Moment 3 (M3): at the second follow-up medical visit (usually after 6 to 9 months after treatment). Mean vaginal squeeze pressure levels were determined by PNM and muscle electromyographic activity by EMG and the results were evaluated by Generalized Linear Model comparisons. RESULTS: Forty-nine patients were evaluated at M1; 35 at M2; and 32 at M3, so that 32 patients had all three muscle evaluations performed. There was a statistically significant increase in the frequency of women with urgency urinary incontinence at the M2 evaluation time (41.9%), compared to pretreatment M1 (18.6%), p<0.001. The means of the vaginal squeeze pressures reduced through M1 to M3 in the phasic (M1: 17.7 mmHg; M3: 11.27mmHg) and tonic contractions (M1: 10.56 mmHg; M3: 7.52mmHg), p = 0.01 and p = 0.03 respectively. There was no difference in pelvic floor function in the three evaluations M1-M3, measured by EMG. The pelvic floor strength assessed by PMN and their interactions with anthropometric, parity and hormonal status variables, showed that a high body mass index (BMI) significantly influenced decreases in pelvic floor muscle function before and after treatment. CONCLUSION: These results show that chemoradiation causes reduction of muscle function of the pelvic floor, especially in the late phase after the end of treatment. Both the high BMI and urgent urinary incontinence symptoms were related to decreased muscle strength. Public Library of Science 2020-06-12 /pmc/articles/PMC7292417/ /pubmed/32530941 http://dx.doi.org/10.1371/journal.pone.0234389 Text en © 2020 Miguel et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Miguel, Taís Pereira
Laurienzo, Carla Elaine
Faria, Eliney Ferreira
Sarri, Almir José
Castro, Isabela Queiroz
Júnior, Renato José Affonso
da Cunha Andrade, Carlos Eduardo Mattos
Vieira, Marcelo de Andrade
dos Reis, Ricardo
Chemoradiation for cervical cancer treatment portends high risk of pelvic floor dysfunction
title Chemoradiation for cervical cancer treatment portends high risk of pelvic floor dysfunction
title_full Chemoradiation for cervical cancer treatment portends high risk of pelvic floor dysfunction
title_fullStr Chemoradiation for cervical cancer treatment portends high risk of pelvic floor dysfunction
title_full_unstemmed Chemoradiation for cervical cancer treatment portends high risk of pelvic floor dysfunction
title_short Chemoradiation for cervical cancer treatment portends high risk of pelvic floor dysfunction
title_sort chemoradiation for cervical cancer treatment portends high risk of pelvic floor dysfunction
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292417/
https://www.ncbi.nlm.nih.gov/pubmed/32530941
http://dx.doi.org/10.1371/journal.pone.0234389
work_keys_str_mv AT migueltaispereira chemoradiationforcervicalcancertreatmentportendshighriskofpelvicfloordysfunction
AT laurienzocarlaelaine chemoradiationforcervicalcancertreatmentportendshighriskofpelvicfloordysfunction
AT fariaelineyferreira chemoradiationforcervicalcancertreatmentportendshighriskofpelvicfloordysfunction
AT sarrialmirjose chemoradiationforcervicalcancertreatmentportendshighriskofpelvicfloordysfunction
AT castroisabelaqueiroz chemoradiationforcervicalcancertreatmentportendshighriskofpelvicfloordysfunction
AT juniorrenatojoseaffonso chemoradiationforcervicalcancertreatmentportendshighriskofpelvicfloordysfunction
AT dacunhaandradecarloseduardomattos chemoradiationforcervicalcancertreatmentportendshighriskofpelvicfloordysfunction
AT vieiramarcelodeandrade chemoradiationforcervicalcancertreatmentportendshighriskofpelvicfloordysfunction
AT dosreisricardo chemoradiationforcervicalcancertreatmentportendshighriskofpelvicfloordysfunction